Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Footnotes
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Corrigendum Open Access | 10.1172/JCI169317

RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass

Nicolas Bonnet, Lucie Bourgoin, Emmanuel Biver, Eleni Douni, and Serge Ferrari

Find articles by Bonnet, N. in: PubMed | Google Scholar

Find articles by Bourgoin, L. in: PubMed | Google Scholar

Find articles by Biver, E. in: PubMed | Google Scholar

Find articles by Douni, E. in: PubMed | Google Scholar

Find articles by Ferrari, S. in: PubMed | Google Scholar

Published February 15, 2023 - More info

Published in Volume 133, Issue 4 on February 15, 2023
J Clin Invest. 2023;133(4):e169317. https://doi.org/10.1172/JCI169317.
© 2023 strength et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published February 15, 2023 - Version history
View PDF

Related article:

RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass
Nicolas Bonnet, … , Eleni Douni, Serge Ferrari
Nicolas Bonnet, … , Eleni Douni, Serge Ferrari
Research Article Bone biology Muscle biology

RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass

  • Text
  • PDF
Abstract

Receptor activator of NF-κB ligand (RANKL) activates, while osteoprotegerin (OPG) inhibits, osteoclastogenesis. A neutralizing Ab against RANKL, denosumab, improves bone strength in osteoporosis. OPG also improves muscle strength in mouse models of Duchenne’s muscular dystrophy (mdx) and denervation-induced atrophy, but its role and mechanisms of action on muscle weakness in other conditions remain to be investigated. We investigated the effects of RANKL inhibitors on muscle in osteoporotic women and mice that either overexpress RANKL (HuRANKLTg+), or lack Pparb and concomitantly develop sarcopenia (Pparb–/–). In women, taking denosumab for more than 3 years improved appendicular lean mass and handgrip strength compared with no treatment, whereas bisphosphonate did not. HuRANKLTg+ mice displayed lower limb force and maximal speed, while their leg muscle mass was diminished, with a lower number of type I and II fibers. Both OPG and denosumab increased limb force proportionally to the increase in muscle mass. They markedly improved muscle insulin sensitivity and glucose uptake, and decreased antimyogenic and inflammatory gene expression in muscle, such as myostatin and protein tyrosine phosphatase receptor-γ. Similarly, in Pparb–/–, OPG increased muscle volume and force while also normalizing insulin signaling and higher expression of inflammatory genes in skeletal muscle. In conclusion, RANKL deteriorates while its inhibitors improve muscle strength and insulin sensitivity in osteoporotic mice and humans. Hence, denosumab could represent a novel therapeutic approach for sarcopenia.

Authors

Nicolas Bonnet, Lucie Bourgoin, Emmanuel Biver, Eleni Douni, Serge Ferrari

×

Original citation: J Clin Invest. 2019;129(8):3214–3223. https://doi.org/10.1172/JCI125915

Citation for this corrigendum: J Clin Invest. 2023;133(4):169317. https://doi.org/10.1172/JCI169317

The authors recently became aware that an incorrect image was shown in Figure 6F for the Pparb–/– Opg-Fc sample. The correct figure is shown below.

Bone, muscle, and glucose phenotype of Pparb–/– mice treated by OPG-Fc.Figure 6

Bone, muscle, and glucose phenotype of Pparb–/– mice treated by OPG-Fc. (A and B) Skeletal muscle volume of the limb and fat infiltration in muscle evaluated by in vivo microCT. (C) Maximal speed evaluated on treadmill normalized by gastrocnemius mass. (D) Limb force evaluated by handgrip normalized by gastrocnemius mass (n = 8 per group). (E) Body temperature evaluated by infrared camera (n = 8 per group). (F) Muscle fiber type, number, and area. Note the type I fibers in blue dark and type II fibers in light blue. Original magnification is ×10. (G) ITT AUC (n = 8 per group). (H) GTT. (I) Relative protein expression in the gastrocnemius. Hatch marks correspond to mice that have received an acute injection of insulin. (J) Relative mRNA expression of insulin signaling in soleus. (K) Relative mRNA expression of Nfkb signaling in soleus (n = 6 per group). Statistical differences were assessed by 1-way ANOVA. †P < 0.05, ‡P < 0.01 significant difference versus WT. Bars show mean ± SEM.

The authors regret the error.

Footnotes

See the related article at RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass.

Version history
  • Version 1 (February 15, 2023): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Footnotes
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts